Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (25.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 25.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
| 12.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 21.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 31.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Cert |
| 07.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Cert |
| 05.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | . ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Office |
| 08.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai |
| 06.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
Stammdaten
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Unternehmen & Branche
| Name | Alkermes plc. |
|---|---|
| Ticker | ALKS |
| CIK | 0001520262 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,66 Mrd. USD |
| Beta | 0,39 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,475,899,000 | 241,664,000 | 1.43 | 2,486,993,000 | 1,819,295,000 |
| 2025-09-30 | 10-Q | 394,185,000 | 82,761,000 | 0.49 | 2,329,512,000 | 1,733,432,000 |
| 2025-06-30 | 10-Q | 390,657,000 | 87,098,000 | 0.52 | 2,252,809,000 | 1,624,584,000 |
| 2025-03-31 | 10-Q | 306,510,000 | 22,464,000 | 0.13 | 2,081,977,000 | 1,511,583,000 |
| 2024-12-31 | 10-K | 1,557,632,000 | 367,070,000 | 2.17 | 2,055,567,000 | 1,464,977,000 |
| 2024-09-30 | 10-Q | 378,143,000 | 92,381,000 | 0.55 | 2,155,291,000 | 1,292,106,000 |
| 2024-06-30 | 10-Q | 399,131,000 | 91,358,000 | 0.53 | 2,206,842,000 | 1,284,005,000 |
| 2024-03-31 | 10-Q | 350,372,000 | 36,828,000 | 0.21 | 2,123,896,000 | 1,254,763,000 |
| 2023-12-31 | 10-K | 1,663,405,000 | 355,757,000 | 2.10 | 2,136,223,000 | 1,202,686,000 |
| 2023-09-30 | 10-Q | 380,938,000 | 47,758,000 | 0.28 | 2,279,231,000 | 1,355,583,000 |
| 2023-06-30 | 10-Q | 617,397,000 | 237,065,000 | 1.38 | 2,187,184,000 | 1,280,437,000 |
| 2023-03-31 | 10-Q | 287,595,000 | -41,845,000 | -0.25 | 1,922,727,000 | 1,005,576,000 |
| 2022-12-31 | 10-K | 1,111,795,000 | -158,267,000 | -0.97 | 1,963,978,000 | 1,043,753,000 |
| 2022-09-30 | 10-Q | 252,357,000 | -63,974,000 | -0.39 | 1,941,899,000 | 1,042,854,000 |
| 2022-06-30 | 10-Q | 276,219,000 | -30,136,000 | -0.18 | 1,957,417,000 | 1,082,324,000 |
| 2022-03-31 | 10-Q | 278,545,000 | -35,903,000 | -0.22 | 1,977,845,000 | 1,075,390,000 |
| 2021-12-31 | 10-K | 1,173,751,000 | -48,169,000 | -0.29 | 2,024,484,000 | 1,112,584,000 |
| 2021-09-30 | 10-Q | 294,141,000 | -28,988,000 | -0.18 | 1,995,432,000 | 1,096,168,000 |
| 2021-06-30 | 10-Q | 303,717,000 | 2,364,000 | 0.01 | 1,937,569,000 | 1,097,902,000 |
| 2021-03-31 | 10-Q | 251,430,000 | -22,418,000 | 1,878,221,000 | 1,051,155,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2,034 | 34.57 | -70,315.38 | -27,6% | |
| 2026-04-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 35.51 | -319,604.40 | -125,5% | |
| 2026-03-03 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2,034 | 29.76 | -60,531.84 | -23,8% | |
| 2026-03-02 | Nichols Christian Todd | Officer, SVP, Chief Commercial Officer | Open Market Sale | -6,000 | 30.00 | -180,000.00 | -70,7% | |
| 2026-03-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 29.72 | -267,485.40 | -105,0% | |
| 2026-03-02 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2,034 | 29.29 | -59,575.86 | -23,4% | |
| 2026-03-02 | Parisi Samuel Joseph | Officer, VP, Finance (Interim PAO) | Open Market Sale | -6,890 | 29.29 | -201,808.10 | -79,2% | |
| 2026-02-02 | Cooke Shane | Director | Open Market Sale | -32,113 | 34.78 | -1,116,877.29 | -438,5% | |
| 2026-02-02 | Cooke Shane | Director | Open Market Sale | -29,087 | 34.34 | -998,795.22 | -392,1% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 33.54 | -134,160.00 | -52,7% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 34.24 | -171,224.50 | -67,2% | |
| 2026-01-08 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 30.00 | -150,005.00 | -58,9% | |
| 2026-01-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 28.00 | -112,000.00 | -44,0% | |
| 2025-12-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -3,748 | 30.00 | -112,447.12 | -44,1% | |
| 2025-12-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 29.30 | -117,200.00 | -46,0% | |
| 2025-11-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 30.38 | -273,441.60 | -107,4% | |
| 2025-10-15 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 31.53 | -283,776.30 | -111,4% | |
| 2025-06-10 | Nichols Christian Todd | Officer, SVP, Chief Commercial Officer | Open Market Sale | -3,334 | 31.09 | -103,654.06 | -40,7% | |
| 2025-06-09 | Nichols Christian Todd | Officer, SVP, Chief Commercial Officer | Open Market Sale | -3,333 | 31.95 | -106,489.35 | -41,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.